Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR.B7-H3 T cells in Recurrent or Refractory Glioblastoma
NCT05366179Phase 1Recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Sep 2022
- Primary completion
- May 2030
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iC9-CAR.B7-H3 T cells in glioblastoma multiforme (GBM), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoints: Number of participants with adverse event at 10 weeks, Cytokine Release Syndrome at 10 weeks and 1 more. Started Sep 2022; status: recruiting.
02
Drugs
iC9-CAR.B7-H3 T cells
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT05366179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05366179.